Adalvo has received DCP approval for our generic Linagliptin 5mg film-coated tablet. We have also been awarded Marketing Authorization (MA) for Spain.
Linagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
The approval opens a clear pathway for partners across multiple European markets, while the Spanish MA provides an immediate commercial opportunity, enabling a February 2027 launch. It also reflects our commitment to expanding access to effective, high-quality diabetes treatments across Europe.
Linagliptin is a well-established therapy with a strong clinical profile, and we are well-positioned to support partners looking to bring it to market.
To discuss licensing opportunities, or to see our full range of diabetes therapies, contact one of the team today.